Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in adult cohort: a real‐life Italian tertiary centre experience
Author:
Affiliation:
1. Medical Sciences Department Dermatologic Clinic University of Turin Turin Italy
2. Faculty of Medicine University of Turin Turin Italy
Publisher
Wiley
Subject
Infectious Diseases,Dermatology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.16219
Reference10 articles.
1. Atopic dermatitis
2. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
3. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
4. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t
5. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I
Cited by 23 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis and comorbid allergies;Allergy;2023-11-21
2. Effect of abrocitinib and dupilumab on eosinophil levels in patients with moderate‐to‐severe atopic dermatitis;JEADV Clinical Practice;2023-06-23
3. Long‐term psychological outcome of patients with moderate‐to‐severe atopic dermatitis continuously treated with Dupilumab: Data up to 3 years;Experimental Dermatology;2023-03-10
4. Lichen ruber planus arising during dupilumab treatment for atopic dermatitis;Italian Journal of Dermatology and Venereology;2022-10
5. Impact of comorbidities in the response of atopic patients treated with dupilumab: a real‐life study up to 36 weeks;Journal of the European Academy of Dermatology and Venereology;2022-07-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3